The FDA granted orphan designation to GlaxoSmithKline Research & Development Limited’s treatment of autosomal dominant polycystic kidney disease, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Executes Share Buyback as Part of Capital Management Strategy
- GSK’s gepotidacin approved by U.K. MHRA
- GSK’s Promising Phase 3 Study on Multiple Myeloma Treatment: A Market Game Changer?
- GSK’s Promising Phase 3 Study on Relapsed SCLC: A Potential Game Changer
- Veeva highlights GSK Vault CRM go-live across Europe